Verastem will launch a U.S. phase 1/2a trial of oral KRAS G12D inhibitor VS-7375 after FDA IND clearance, with data to be ...

Molecular Partners (MOLN) announced the presentation of three posters at the American Association for Cancer Research annual meeting 2025, ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment ...

Q1 2025 Earnings Call Transcript April 24, 2025 NovoCure Limited beats earnings expectations. Reported EPS is $-0.31, ...

A program cochair said the agenda was designed to get attendees "out of their comfort zone." The Amercian Association for ...

Q1 2025 Management View Executive Chairman Bill Doyle highlighted the company’s transition to a multi-indication oncology ...

NovoCure posted stronger-than-expected Q1 2025 results, driven by revenue and GAAP earnings surpassing estimates.

BioAtla (BCAB) announced preclinical poster presentations at the upcoming 2025 American Association for Cancer Research to be held at the ...

Partnered Assets: SIRPa antagonists BI 765063 and BI 770371, an improved next generation SIRPa inhibitor, developed in partnership with Boehringer Ingelheim: Rapid Oral Abstracts of the Phase 1 ...

Details of the acimtamig oral presentation and AFM24 poster presentations are as follows: The full abstracts will be published online on May 22, 2025. More details about the programs for the 2025 ASCO ...